Zookeepers spent three years teaching 16-year-old Mahiri how to confidently use an inhaler, which Banham Zoo designed to ...
Abstract: This study presents a wireless, integrated, and portable monitoring system for chronic obstructive pulmonary disease (COPD), featuring a highly sensitive and wide dynamic range MEMS-based ...
LA JOLLA, Calif.--(BUSINESS WIRE)--#Biotech--AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory ...
The initiation of tiotropium monotherapy was associated with, at most, a modest increase in dementia risk among older adults with chronic obstructive pulmonary disease (COPD) compared with long-acting ...
GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic ...
A Johns Hopkins Medicine-led analysis of medical information gathered on a diverse group of almost 250,000 people over four years has significantly clarified the link between the "exclusive" use of ...
Please provide your email address to receive an email when new articles are posted on . Several European studies have investigated integrating spirometry at the time of low-dose CT. Spirometry needs ...
Following my heart and lung transplant in 2018, I really wanted a smartwatch. Admittedly, the dream was that I’d be using this piece of tech to track ambitious hikes and long walks. Maybe even runs. I ...
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab). The ...
GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal antibody that targets interleukin-5, as an add-on ...
Background and Goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have ...